Format

Send to

Choose Destination
Prescrire Int. 2009 Jun;18(101):114.

Ramelteon: application withdrawn. Ramelteon in insomnia: withdrawal of marketing application in patients' best interests.

[No authors listed]

Abstract

The European Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the use of the melatonin receptor agonist ramelteon in insomnia, due to its unfavourable risk-benefit balance. In France, melatonin itself is licensed for use in this indication.

PMID:
19639675
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center